AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Q2 FY25 Total Income was at Rs. 85.4 crore
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Subscribe To Our Newsletter & Stay Updated